1Division of Nephrology and Hypertension, Department of Medicine, Department of Physiology and Pharmacology, Heart Research Center, Oregon Health and Science University, Portland, Oregon, USA. 2VA Medical Center, Portland, Oregon, USA.
Address correspondence to: David H. Ellison, Division of Nephrology and Hypertension, CH12R, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, Oregon 97239, USA. Phone: 503.494.8490; Fax: 503.494.5330; E-mail: firstname.lastname@example.org.
First published January 25, 2013 - More info
See the related article beginning on page 657.
Liddle syndrome is monogenic hypertension caused by mutations in the epithelial Na+ channel (ENaC) that interfere with its ubiquitylation by Nedd4-2. In this issue, Ronzaud and colleagues found that deleting Nedd4-2 from kidney tubules in adult mice led to ENaC accumulation, but not at the plasma membrane, as predicted from current models. Instead, abundance of the sodium chloride transporter NCC increased at the plasma membrane, and the mice have some features of increased NCC activity. Together, the results suggest that defective ubiquitylation of ENaC by Nedd4-2 may not fully explain Liddle syndrome and that Nedd4-2 modulates NCC more strongly.
Because something is happening here
But you don’t know what it is
Do you, Mister Jones?
“Ballad of A Thin Man” (1965)
Liddle syndrome is a monogenic hypertensive disease that results from excess activity of the epithelial sodium channel ENaC (1). In 1996, Staub, Rotin, and colleagues found that the ubiquitin ligase Nedd 4-2 interacts with ENaC via PY motifs within the carboxyl terminal domains of ENaC subunits (1). The disease-causing mutations in the β- or γENAC subunits result in deletion of the PY motifs (2), which abrogates ubiquitylation of the channel in vitro (3). As ubiquitylation of proteins appears to accelerate their removal from the plasma membrane and to increase degradation (or recycling), these deletions are expected to result in an increase in ENaC at the plasma membrane, an effect that has been observed both in vitro (3) and in vivo (4); mice with a mutated βENaC also exhibit many of the phenotypic features of Liddle syndrome, supporting the fidelity of this model (4).
Although attention has focused on the ability of Nedd4-2 to modulate ENaC, it may also interact with another sodium transport protein expressed by the distal nephron, the thiazide-sensitive Na+Cl– cotransporter (NCC, SLC12A3). Ko and colleagues reported that NCC is ubiquitylated, and suggested that this process might be involved in its endocytosis (5). Arroyo et al. reported that NCC coimmunoprecipitates with Nedd4-2 when transfected into HEK293 cells and that coexpression of Nedd4-2 with NCC inhibited NCC activity in oocytes (6). Surprisingly, however, the interaction of Nedd4-2 with NCC did not occur through classical PY motifs, suggesting that the interaction occurs via alternative domains. Thus, emerging evidence posits a role for Nedd4-2 in mediating NCC ubiquitylation and endocytosis.
Nedd4-2 ubiquitin ligase activity is not constitutive, but instead is believed to be important in modulating aldosterone effects on ENaC and perhaps NCC. According to consensus models (Figure 1), aldosterone increases SGK1 expression, which phosphorylates Nedd4-2 on key serine residues, thereby promoting interaction with 14-3-3 proteins. This interaction reduces Nedd4-2’s ubiquitin ligase activity with respect to ENaC. The model suggests that ENaC that is not highly ubiquitylated will remain in the plasma membrane longer (7). This hypothesis is supported by abundant data, but like all models, it must be tested in vivo to confirm its essential features. The paper by Ronzaud and colleagues (8) in this issue of the JCI takes this model out for a test drive, with some very surprising results.
Models of ENaC and NCC regulation by Nedd4-2. (A) Aldosterone (Aldo) interaction with the mineralocorticoid receptor (MR) induces SGK1 activity, which suppresses the ubiquitin ligase activity of Nedd4-2. Nedd4-2 normally catalyzes the addition of ubiquitin moieties (Ub) to ENaC (step i). Ubiquitylated ENaC is then removed from the plasma membrane (step ii) and undergoes degradation (or recycling) inside the cell (step iii). Poorly defined alternate pathways for SGK1 to stimulate ENaC independently of Nedd4-2 also exist. Ronzaud and colleagues (8) found that Nedd4-2 deletion increased in intracellular ENaC, suggesting that Nedd4-2 may affect step iii (dotted blue arrow) more than step ii. (B) Similar signaling pathway to NCC. An alternative pathway for SGK1 activation of NCC may involve WNK4, as described in text. In contrast with effects on ENaC, NCC abundance was increased at the plasma membrane by Nedd4-2 deletion, suggesting a defect at step ii, as shown by the dotted blue arrow. Note that sites of ubiquitylation on NCC have not been defined.
Ronzaud et al. used an inducible tissue-specific recombination strategy to delete Nedd4-2 in the adult nephron (8), a system that circumvents the confounding effects of the gene’s developmental and extrarenal roles (9). As expected, Nedd4-2 deletion led to substantial increases in β- and γENaC abundance. What was unexpected was that the increase was predominantly inside the cell, rather than at the plasma membrane, and that α NaC levels were substantially reduced. Although plasma aldosterone was reduced, suggesting positive sodium balance, the mice did not retain Na abnormally when switched to a high-salt diet, and serum potassium balance remained normal (8); thus, the mouse model does not phenocopy Liddle syndrome. These are striking and confusing results, suggesting on their surface that the consensus model for ENaC regulation by Nedd4-2–mediated ubiquitylation is either incorrect or incomplete. How can they be explained?
A prior study found that arterial pressure and ENaC abundance (including αENaC) were elevated, as expected, when Nedd4-2 was deleted globally (10), but those investigators did not determine whether increased ENaC was located at the plasma membrane or inside the cell. Importantly, aldosterone levels were not suppressed in the global Nedd4-2–knockout animals, in striking contrast with the results obtained by Ronzaud and colleagues and with the findings in individuals with Liddle syndrome. This suggested to the prior investigators (10) that Nedd4-2 plays a role in modulating adrenal aldosterone secretion. As in the nephron-specific deletion model, global deletion of Nedd4-2 did not affect plasma potassium, again differing from the Liddle syndrome phenotype. Ronzaud et al. made an attempt to determine whether the differences between the global Nedd4-2 deletion model and the inducible kidney-specific model resulted from developmental or systemic factors by treating pregnant animals with doxycycline to delete Nedd4-2 in the kidney embryonically. The resulting phenotype, including the suppressed aldosterone, was essentially identical to that observed when Nedd4-2 was deleted in the kidney in adulthood (9). Taken together, these results suggest the provocative hypothesis that the major effect of Nedd4-2 on ENaC is to modulate intracellular degradation (step iii in Figure 1A) rather than removal from the plasma membrane (step ii in Figure 1A); the abundance of αENaC is then likely regulated primarily by aldosterone.
One final possible explanation for the surprising results should be noted. Although both the nephron-specific (8) and global Nedd4-2–knockout (10) mice are viable and appear healthy, a third model of Nedd4-2–knockout exhibited perinatal mortality due to pulmonary dysfunction (11). Both of the viable models inactivate Nedd4-2 by deleting exons 6–8, while the mice with lethality had exons 15 and 16 deleted. Boase and colleagues (11) showed that deleting exons 6–8 results in exon skipping and the formation of truncated Nedd4-2 peptides and suggested that the residual function of these truncated forms abrogates perinatal lethality. Ronzaud et al. used several antibodies to provide evidence that production of such aberrant Nedd4-2 products does not occur, at least in the kidneys of their model (8). While these results are reassuring, an inducible nephron-specific Nedd4-2 model in which exons 15 and 16 are deleted should be generated to explore this difference.
The other notable result of the studies of Ronzaud and colleagues is that Nedd4-2 deletion led to a substantial increase in NCC abundance; this time, the increase appears to be primarily at the apical membrane, and the transporter appears to be active (8). This in vivo evidence that Nedd4-2–dependent ubiquitylation modulates NCC retention in the apical membrane is of particular interest because mutations in other proteins involved in ubiquitylation reactions, kelch-like 3 and cullin 3, are linked to human hypertension (12, 13), presumably because they result in membrane NCC accumulation. However, the roles of RING E3 ligases, such as kelch-like 3, have generally been found to be distinct from those of Hect E3 ligases, such as Nedd4-2 (14); thus, it remains unclear how the roles of the two classes of ubiquitin ligases interact to modulate NCC activity.
The increased abundance of NCC in the Nedd4-2–knockout animals is a mirror image of decreased NCC abundance that results from inducible kidney-specific SGK1 deletion (15). This suggests that Nedd4-2 in the distal convoluted tubule (DCT) may be part of an aldosterone/SGK1/Nedd4-2/NCC signaling pathway (involving steps i and ii in Figure 1B). As noted, while SGK1 was identified initially as a component of the signaling pathway linking aldosterone to ENaC, it has been increasingly recognized that aldosterone and SGK1 also modulate NCC (16) and that this effect may be physiologically important. What is most impressive in the paper by Ronzaud and colleagues (8) is that NCC levels are increased despite low plasma aldosterone levels; this suggests that Nedd4-2 plays an essential role in aldosterone signaling to NCC. One note of caution, however, is needed: lest we conclude that indeed Nedd4-2 is more important to signal NCC than ENaC, Loffing-Cueni and colleagues (17) reported previously that Nedd4-2 abundance is much lower and less subject to regulation along the NCC-expressing DCT than along the ENaC-expressing connecting tube (CNT). In the current work, we are not told whether dietary salt intake still affects NCC activity.
Given the above, what can we conclude concerning the role of SGK1 and Nedd4-2 along the nephron? First, it seems that aldosterone, and probably SGK1, increase apical ENaC abundance largely through signaling mechanisms that do not require Nedd4-2. This conclusion derives not only from the current paper (8), but also from work showing that aldosterone responsiveness of ENaC in the rectum is increased rather than decreased when Nedd4-2 is deleted (18) and that aldosterone still regulates ENaC trafficking in the kidney when PY motifs are deleted in vivo (4). One possibility, suggested by the current results, is that Nedd4-2–mediated ubiquitylation primarily accelerates ENaC degradation within the cell (step iii in Figure 1A) rather than its removal from the membrane (step ii in Figure 1A). Secondly, Nedd4-2 appears to play a physiologically significant and nonredundant role in modulating NCC abundance. That said, it should be pointed out that SGK1 also activates NCC through pathways independently of Nedd4-2 (16) and that other NCC modulators, such as WNK4, may also have large effects on NCC activity. Finally, this work shows again why it is so important to test mechanistic models in vivo. While the results are sometimes confusing and can challenge accepted dogma, their relevance to human health and disease is beyond question. An intriguing clinical implication of the paper by Ronzaud and colleagues (8) is that manipulating Nedd4-2 activity might be a novel approach to treating Gitelman syndrome, an ionic imbalance disease linked to reductions in membrane NCC (19). As Nedd4-2 may inhibit both membrane removal and intracellular degradation, its inhibition might increase NCC abundance enough to ameliorate the troubling symptoms of the disease.
The author acknowledges the review and suggestions provided by James McCormick. The author’s laboratory is supported by funds from the Department of Veterans Affairs and the NIH (DK 5 RO1 51496 and DK 1 RO1 095841).
Conflict of interest: The author has declared that no conflict of interest exists.
Citation for this article:J Clin Invest. 2013;123(2):546–548. doi:10.1172/JCI66882.
See the related article beginning on page 657.
Copyright © 2016 American Society for Clinical Investigation